Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Humans
Receptors, Chimeric Antigen
Prospective Studies
Neoplasm Recurrence, Local
Positron-Emission Tomography
/ methods
Positron Emission Tomography Computed Tomography
Prognosis
Lymphoma, B-Cell
Fluorodeoxyglucose F18
T-Lymphocytes
Retrospective Studies
Lymphoma, Large B-Cell, Diffuse
/ diagnostic imaging
CAR T-cell
Deauville score
PET
SUV
lymphoma
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 01 2023
15 01 2023
Historique:
revised:
14
09
2022
received:
09
06
2022
accepted:
27
09
2022
pubmed:
18
11
2022
medline:
24
12
2022
entrez:
17
11
2022
Statut:
ppublish
Résumé
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk for relapse or progression after CAR T-cell therapy represents a clinical need. The authors conducted a single-center prospective study on 47 relapsed/refractory LBCL receiving CAR T-cell therapy to evaluate the prognostic value of baseline and after infusion Deep variation of standardized uptake value (SUV) PET parameters and association of DS and variation of SUV This is a single-center prospective study on 47 lymphoma patients receiving commercial chimeric antigen receptor T-cell therapy aimed to evaluate the prognostic value of baseline and after infusion
Sections du résumé
BACKGROUND
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk for relapse or progression after CAR T-cell therapy represents a clinical need.
METHODS
The authors conducted a single-center prospective study on 47 relapsed/refractory LBCL receiving CAR T-cell therapy to evaluate the prognostic value of baseline and after infusion
RESULTS
Deep variation of standardized uptake value (SUV)
CONCLUSIONS
PET parameters and association of DS and variation of SUV
LAY SUMMARY
This is a single-center prospective study on 47 lymphoma patients receiving commercial chimeric antigen receptor T-cell therapy aimed to evaluate the prognostic value of baseline and after infusion
Identifiants
pubmed: 36385707
doi: 10.1002/cncr.34532
pmc: PMC10099560
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
255-263Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Blood Adv. 2020 Jul 28;4(14):3268-3276
pubmed: 32702097
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Med Image Comput Comput Assist Interv. 2006;9(Pt 2):782-9
pubmed: 17354844
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
J Clin Epidemiol. 1995 Dec;48(12):1503-10
pubmed: 8543964
Blood Adv. 2022 May 10;6(9):2867-2871
pubmed: 35015825
Gynecol Oncol. 2012 Oct;127(1):131-5
pubmed: 22772064
Stat Med. 1989 May;8(5):551-61
pubmed: 2657958
Ann Hematol. 2021 Sep;100(9):2303-2310
pubmed: 34236497
Blood Adv. 2020 Mar 24;4(6):1082-1092
pubmed: 32196557
Blood. 2020 Apr 16;135(16):1396-1405
pubmed: 31978225
Lancet Oncol. 2021 Oct;22(10):1403-1415
pubmed: 34516954
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
J Clin Oncol. 2020 Sep 20;38(27):3119-3128
pubmed: 32401634
EJNMMI Res. 2018 Apr 11;8(1):29
pubmed: 29644499
Haematologica. 2022 Jul 01;107(7):1633-1642
pubmed: 34407602
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood Adv. 2020 Oct 13;4(19):4898-4911
pubmed: 33035333
Blood. 2011 Jul 7;118(1):37-43
pubmed: 21518924
Blood Adv. 2022 Jan 11;6(1):321-326
pubmed: 34700342
J Clin Epidemiol. 2004 Dec;57(12):1262-70
pubmed: 15617952
Blood Adv. 2020 Nov 24;4(22):5607-5615
pubmed: 33180899
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22
pubmed: 24902639
Cancer. 2023 Jan 15;129(2):255-263
pubmed: 36385707